Eagle Asset Management Inc. Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Eagle Asset Management Inc. reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 37.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 176,249 shares of the company’s stock after selling 106,102 shares during the period. Eagle Asset Management Inc. owned approximately 0.14% of Vaxcyte worth $18,800,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares during the period. RA Capital Management L.P. raised its holdings in Vaxcyte by 4.0% in the 1st quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after buying an additional 312,500 shares during the period. Janus Henderson Group PLC raised its holdings in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after buying an additional 692,492 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after buying an additional 498,359 shares during the period. Finally, Darwin Global Management Ltd. raised its holdings in Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after buying an additional 2,170,845 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at $10,429,294.37. This represents a 31.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,464 shares of company stock valued at $11,455,576. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Up 0.2 %

Shares of PCVX opened at $88.54 on Friday. The stock has a 50 day moving average price of $107.89 and a 200 day moving average price of $89.26. Vaxcyte, Inc. has a 52-week low of $48.24 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PCVX shares. Needham & Company LLC reiterated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Leerink Partners boosted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Finally, Bank of America boosted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.